Comparative study the use of metformin versus placebo for prophylaxis from gestational diabetes in high risk patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201503001059248

Enrollment

300

Registered

2015-03-06

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine Pregnancy and Childbirth gestational diabetes

Interventions

Metformin medication

Placebo in th form of pyridoxine tablets

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: i. Obese patients with body mass index above 30. ii. Patients with history of gestational diabetes. iii. Patients with history of gestational diabetes in previous pregnancies. iv. Patients with multiple gestation. v. Pateints with family history of gestational diabetes in siblings or type 2 diabetes in parents. vi. Patients with polycystic ovarian disease

Exclusion criteria

Exclusion criteria: 1- Patients with pre-gestational diabetes 2- Patients with intolerance to metformin e.g. hypersensitivity to the medication.

Design outcomes

Primary

Measure	Time frame
prevention of gestational diabetes	—

Secondary

Measure	Time frame
prevention of maternal or fetal complications	—

Countries

Egypt

Contacts

Public ContactTamer Abdel Dayem

lecturer of obstetrics-University of Alexandria

tmdaeim@gmail.com00201226720766

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026